These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
93 related items for PubMed ID: 6124259
1. Binding of [3H]ADTN to rat striatal membranes. Templeton WW, Woodruff GN. Biochem Pharmacol; 1982 Apr 15; 31(8):1629-32. PubMed ID: 6124259 [Abstract] [Full Text] [Related]
2. Striatal binding of 2-amino-6,7-[3H]dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics. List SJ, Wreggett KA, Seeman P. J Neurosci; 1982 Jul 15; 2(7):895-906. PubMed ID: 6124583 [Abstract] [Full Text] [Related]
3. Ascorbic acid and membrane ageing: critical determinants of the in-vitro binding of [3H]ADTN to rat striatal tissue. Bradbury AJ, Costall B, Naylor RJ. J Pharm Pharmacol; 1983 Nov 15; 35(11):738-45. PubMed ID: 6139456 [Abstract] [Full Text] [Related]
4. Kinetic and pharmacological profiles of the in vitro binding of the potent dopamine agonist [3H]N,N-dipropyl-5,6-dihydroxy-2-aminotetralin to rat striatal membranes. Mulder TB, Grol CJ, Dijkstra D, Horn AS. Eur J Pharmacol; 1985 May 28; 112(1):73-9. PubMed ID: 4018139 [Abstract] [Full Text] [Related]
5. Altered characteristics of striatal [3H]ADTN binding following substantia nigra lesions. Hirschhorn ID, Makman MH. Eur J Pharmacol; 1982 Sep 10; 83(1-2):61-7. PubMed ID: 7128701 [Abstract] [Full Text] [Related]
6. Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors. Seeman P, Woodruff GN, Poat JA. Eur J Pharmacol; 1979 Apr 15; 55(2):137-42. PubMed ID: 456412 [Abstract] [Full Text] [Related]
7. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand. Clement-Cormier Y, Abel M. Res Commun Chem Pathol Pharmacol; 1978 Oct 15; 22(1):15-25. PubMed ID: 725314 [Abstract] [Full Text] [Related]
8. Changes in (3H)-ADTN binding to microsomal and synaptic membrane fractions from rat striata following kainic acid lesions. Davis A, Woodruff GN, Poat JA, Freedman SB. Biochem Pharmacol; 1980 Jun 15; 29(12):1645-8. PubMed ID: 7406893 [No Abstract] [Full Text] [Related]
9. Properties of dopamine agonist and antagonist binding sites in mammalian retina. Makman MH, Dvorkin B, Horowitz SG, Thal LJ. Brain Res; 1980 Aug 04; 194(2):403-18. PubMed ID: 6770965 [Abstract] [Full Text] [Related]
10. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects. Rollema H, Feenstra MG, Grol CJ, Lewis MH, Staples L, Mailman RB. Naunyn Schmiedebergs Arch Pharmacol; 1986 Apr 04; 332(4):338-45. PubMed ID: 3736679 [Abstract] [Full Text] [Related]
11. Chronic D-amphetamine and phencyclidine: effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems. Robertson HA. Brain Res; 1983 May 09; 267(1):179-82. PubMed ID: 6860944 [Abstract] [Full Text] [Related]
19. In vivo displacement by 3-PPP enantiomers of N,N-dipropyl-5,6-ADTN from dopamine receptor-binding sites in rat striatum. Carlsson A, Löfberg L. J Neural Transm; 1985 May 09; 64(3-4):173-85. PubMed ID: 4086990 [Abstract] [Full Text] [Related]